S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

$15.61
-0.46 (-2.86%)
(As of 04/19/2024 ET)
Today's Range
$15.24
$16.33
50-Day Range
$13.31
$21.47
52-Week Range
$4.29
$21.88
Volume
1.05 million shs
Average Volume
1.38 million shs
Market Capitalization
$976.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

MacroGenics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
8.9% Upside
$17.00 Price Target
Short Interest
Bearish
11.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.25mentions of MacroGenics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.06 out of 5 stars

Medical Sector

376th out of 909 stocks

Pharmaceutical Preparations Industry

166th out of 424 stocks

MGNX stock logo

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

MGNX Stock News Headlines

MacroGenics, Inc. (MGNX)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
The Latest Analyst Ratings For Macrogenics
MGNX Apr 2024 10.000 put
MGNX Dec 2024 17.500 put
MGNX Mar 2024 22.500 put
MacroGenics price target raised by $12 at Citi, here's why
MacroGenics (NASDAQ: MGNX)
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MGNX
Employees
339
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$24.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+8.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-9,060,000.00
Pretax Margin
-15.42%

Debt

Sales & Book Value

Annual Sales
$58.75 million
Book Value
$2.46 per share

Miscellaneous

Free Float
56,305,000
Market Cap
$976.56 million
Optionable
Optionable
Beta
2.09

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Scott Koenig M.D. (Age 72)
    Ph.D., President, CEO & Director
    Comp: $1.06M
  • Mr. James KarrelsMr. James Karrels (Age 57)
    Senior VP, CFO & Corporate Secretary
    Comp: $626.83k
  • Mr. Eric Blasius Risser (Age 51)
    Chief Operating Officer
    Comp: $651.36k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 57)
    Senior Vice President of Technical Operations
    Comp: $550.97k
  • Dr. Ezio Bonvini (Age 70)
    Senior VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Mr. Jeffrey Stuart Peters (Age 53)
    Senior VP, General Counsel & Corporate Compliance Officer
  • Dr. Stephen L. Eck M.D. (Age 69)
    Ph.D., Senior VP of Clinical Development & Chief Medical Officer
    Comp: $577.62k
  • Ms. Lynn Cilinski (Age 66)
    VP, Controller & Treasurer

MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price target for 2024?

8 equities research analysts have issued 1 year price objectives for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2024?

MacroGenics' stock was trading at $9.62 on January 1st, 2024. Since then, MGNX stock has increased by 62.3% and is now trading at $15.61.
View the best growth stocks for 2024 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.49. The biopharmaceutical company earned $10.72 million during the quarter, compared to analyst estimates of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative trailing twelve-month return on equity of 88.49%. During the same quarter in the prior year, the company earned $0.21 earnings per share.

What ETFs hold MacroGenics' stock?
What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional investors include Wasatch Advisors LP (1.58%), Los Angeles Capital Management LLC (0.09%), Diversified Trust Co (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Sound Income Strategies LLC (0.01%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners